301226-53-9 Usage
Uses
Used in Pharmaceutical Industry:
BOC-(TRANS)-4-(3-FLUORO-PHENYL)-PYRROLIDINE-3-CARBOXYLIC ACID is used as a precursor compound for the development of pyrrolidinylurea and pyrrolidinylthiourea compounds. These compounds act as TrkA kinase inhibitors, which are important in the regulation of cell growth, survival, and differentiation. By inhibiting TrkA kinase, these compounds can potentially be used in the treatment of various diseases, including neurodegenerative disorders and cancer.
In the synthesis process, BOC-(TRANS)-4-(3-FLUORO-PHENYL)-PYRROLIDINE-3-CARBOXYLIC ACID is utilized to create the core structure of the desired TrkA kinase inhibitors. This allows researchers and pharmaceutical companies to develop new and more effective drugs targeting the TrkA kinase pathway, ultimately leading to improved treatment options for patients.
Check Digit Verification of cas no
The CAS Registry Mumber 301226-53-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,1,2,2 and 6 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 301226-53:
(8*3)+(7*0)+(6*1)+(5*2)+(4*2)+(3*6)+(2*5)+(1*3)=79
79 % 10 = 9
So 301226-53-9 is a valid CAS Registry Number.
InChI:InChI=1/C16H20FNO4/c1-16(2,3)22-15(21)18-8-12(13(9-18)14(19)20)10-5-4-6-11(17)7-10/h4-7,12-13H,8-9H2,1-3H3,(H,19,20)/t12-,13+/m0/s1
301226-53-9Relevant academic research and scientific papers
HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6
-
Paragraph 00392; 00404, (2021/09/04)
The present disclosure relates to compounds capable of modulating the activity of NR2F6. The compounds of the disclosure may be used in methods for the prevention and/or the treatment of diseases and disorders associated with modulating NR2F6 activity.
Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids
-
Page/Page column 24; 25, (2008/06/13)
The present invention relates to a process for the preparation of cis substituted cyclic β-aryl or heteroaryl carboxylic acid derivatives in high diastereo- and enantioselectivity by enantioselective hydrogenation in accordance with the following scheme w
